How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
AMERICAN KRATOM ASSOCIATION via MICKENBERG, LLC
2026 · second_quarter · Q2
Drug Policy Reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN KRATOM ASSOCIATION via MICKENBERG, LLC
2026 · first_quarter · Q1
Source: Senate LDA
Drug Policy Reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN KRATOM ASSOCIATION via MICKENBERG, LLC
2025 · fourth_quarter · Q4
Drug Policy Reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN KRATOM ASSOCIATION via MICKENBERG, LLC
2025 · third_quarter · Q3
Drug Policy Reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN KRATOM ASSOCIATION via MICKENBERG, LLC
2025 · second_quarter · Q2
Drug Policy Reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN KRATOM ASSOCIATION via MICKENBERG, LLC
2025 · second_quarter · Q2
Drug Policy Reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN KRATOM ASSOCIATION via MICKENBERG, LLC
2025 · first_quarter · Q1
Drug Policy Reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN KRATOM ASSOCIATION via MICKENBERG, LLC
2025 · first_quarter · RA
Drug Policy Reform
AMERICAN KRATOM ASSOCIATION via MICKENBERG, LLC
2025 · first_quarter · RR
Drug policy reform related to Kratom